Asuka Minematsu
Overview
Explore the profile of Asuka Minematsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takagi R, Kobayashi S, Yamato M, Owaki T, Kasai Y, Hosoi T, et al.
Regen Ther
. 2019 Jun;
1:1-4.
PMID: 31245435
We have utilized patients' own oral mucosa as a cell source for the fabrication of transplantable epithelial cell sheets to treat limbal stem cell deficiency and mucosal defects after endoscopic...
2.
Minematsu A, Miyazaki T, Shimamura S, Nishikawa H, Nakayama H, Takazono T, et al.
PLoS One
. 2019 Jan;
14(1):e0210883.
PMID: 30673768
Vacuolar proton-translocating ATPase (V-ATPase) is located in fungal vacuolar membranes. It is involved in multiple cellular processes, including the maintenance of intracellular ion homeostasis by maintaining acidic pH within the...
3.
Nagayoshi Y, Miyazaki T, Shimamura S, Nakayama H, Minematsu A, Yamauchi S, et al.
PLoS One
. 2017 Jul;
12(7):e0180990.
PMID: 28700656
The pathogenic fungus Candida glabrata is often resistant to azole antifungal agents. Drug efflux through azole transporters, such as Cdr1 and Cdr2, is a key mechanism of azole resistance and...
4.
Nishikawa H, Miyazaki T, Nakayama H, Minematsu A, Yamauchi S, Yamashita K, et al.
FEMS Yeast Res
. 2016 Jul;
16(5).
PMID: 27370212
Vacuolar H(+)-ATPase (V-ATPase) is responsible for the acidification of eukaryotic intracellular compartments and plays an important role in oxidative stress response (OSR), but its molecular bases are largely unknown. Here,...
5.
Nagayoshi Y, Miyazaki T, Minematsu A, Yamauchi S, Takazono T, Nakamura S, et al.
FEMS Yeast Res
. 2014 Sep;
14(7):1128-31.
PMID: 25175946
Echinocandin-class antifungals, including micafungin, are considered as the first-line treatment for Candida glabrata infections. However, recent epidemiological surveys have revealed an increasing number of C. glabrata isolates exhibiting decreased echinocandin...
6.
Hosogaya N, Miyazaki T, Nagi M, Tanabe K, Minematsu A, Nagayoshi Y, et al.
FEMS Yeast Res
. 2013 Mar;
13(4):411-21.
PMID: 23496820
The pathogenic fungus Candida glabrata is relatively resistant to azole antifungals, which target lanosterol 14α-demethylase (Erg11p) in the ergosterol biosynthesis pathway. Our study revealed that C. glabrata exhibits increased azole...
7.
Minematsu A, Sawai T, Matsutake T, Soejima Y, Naito S, Kohno S
Kansenshogaku Zasshi
. 2011 Nov;
85(5):527-31.
PMID: 22117384
A 78-year-old woman seen in June 2005 for chest abnormal shadows after 3 months of steroid therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies was found in chest computed tomography...
8.
Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, et al.
Antimicrob Agents Chemother
. 2011 Oct;
56(1):584-7.
PMID: 22024829
We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole,...